{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:16Z","timestamp":1791256756704,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ygyno.2015.12.025","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T12:01:43Z","timestamp":1451304103000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)"],"prefix":"10.1016","volume":"140","author":[{"given":"G\u00fcnter","family":"Emons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Neuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-8213","authenticated-orcid":false,"given":"Nikolaus","family":"de Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willibald","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Leonhard","family":"Heubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.12.025_bb0005","series-title":"Cancer Facts and Figures 2014","author":"American Cancer Society","year":"2013"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0010","unstructured":"ECO, European Cancer Observatory. International agency for research on cancer. http:\/\/eu-cancer.iarc.fr (assessed on 16\/05\/2015)."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010482","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","volume":"7","author":"Lawrie","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0025","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian cancer study group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2014.05.018","article-title":"Endometrial cancer: a review and current management strategies: part I","volume":"134","author":"SGO Clinical Practice Endometrial Cancer Working Group","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: a review and current management strategies: part II","volume":"134","author":"SGO Clinical Practice Endometrial Cancer Working Group","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/107327480901600106","article-title":"Current treatment of metastatic endometrial cancer","volume":"16","author":"Temkin","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007926.pub2","article-title":"Hormonal therapy in advanced or recurrent endometrial cancer","volume":"12","author":"Kocka","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer","volume":"137","author":"Mabuchi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0070","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2014.02.017","article-title":"mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review","volume":"133","author":"Husseinzadeh","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0085","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cncr.28414","article-title":"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer","volume":"120","author":"Mackay","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0100","author":"Gynecologic Cancer Intergroup"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0105","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1002\/sim.2866","article-title":"Early stopping designs based on progression free survival at an early time point in the initial cohort","volume":"26","author":"Litwin","year":"2007","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0110","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdf038","article-title":"Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ovarian cancer","volume":"13","author":"du Bois","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"Meier","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2005.11.019","article-title":"Systematic review of systemic therapy for advanced or recurrent endometrial cancer","volume":"101","author":"Carey","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0130","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2003.10.083","article-title":"Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"21","author":"Gallion","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdl417","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration","volume":"18","author":"Humber","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0140","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/annonc\/mdh316","article-title":"Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin +24-h paclitaxel + filgrastim in endometrial carcinoma: a gynecologic oncology group study","volume":"15","author":"Fleming","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0145","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0150","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO","volume":"108","author":"Ray-Coquard","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2015.12.025_bb0155","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2014.06.033","article-title":"Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer","volume":"135","author":"Tsoref","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma","author":"Oza","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ygyno.2013.08.004","article-title":"Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer","volume":"131","author":"Goodwin","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/IGC.0000000000000118","article-title":"The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer","volume":"24","author":"Meyer","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.025_bb0180","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-012-0242-9","article-title":"Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study","volume":"8","author":"Tr\u00e9dan","year":"2013","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0195","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.025_bb0200","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1158\/1078-0432.CCR-13-0615","article-title":"New strategies in endometrial cancer: targeting the PI3K\/mTOR pathway\u2014the devil is in the details","volume":"19","author":"Myers","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T20:22:05Z","timestamp":1567455725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815302298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0090825815302298"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}